Introduction
The low-throughput, resource-intensive process of antibody variant characterization can be a costly bottleneck in the discovery pipeline. Twist High-Throughput Antibody Production is a gene-to-protein workflow that relieves this bottleneck by producing tens to thousands of diverse antibodies for screening biophysical and pharmacokinetic properties. Twist’s silicon-based DNA synthesis platform can precisely write thousands of genes per run, enabling the rapid and high-throughput production of antibodies for discovery and screening.
Product Specifications
- Antibodies provided as purified protein or supernatant
- All major isotypes of IgG available: IgG1, IgG2, IgG4, Kappa and Lambda light chain, and VHH-Fc (IgG1 and IgG2)
- Yields range from 15 μg to 2,000 μg
- Antibodies expressed in HEK-293 cells
Need to expand your capacity for producing antibodies for screening?
Twist High throughput Antibody Production enables immediate expansion of your antibody production pipeline. Simply upload the antibody sequences you need and let Twist do the rest.
Introduction
The low-throughput, resource-intensive process of antibody variant characterization can be a costly bottleneck in the discovery pipeline. Twist High-Throughput Antibody Production is a gene-to-protein workflow that relieves this bottleneck by producing tens to thousands of diverse antibodies for screening biophysical and pharmacokinetic properties. Twist’s silicon-based DNA synthesis platform can precisely write thousands of genes per run, enabling the rapid and high-throughput production of antibodies for discovery and screening.
Product Specifications
- Antibodies provided as purified protein or supernatant
- All major isotypes of IgG available: IgG1, IgG2, IgG4, Kappa and Lambda light chain, and VHH-Fc (IgG1 and IgG2)
- Yields range from 15 μg to 2,000 μg
- Antibodies expressed in HEK-293 cells
Need to expand your capacity for producing antibodies for screening?
Twist High throughput Antibody Production enables immediate expansion of your antibody production pipeline. Simply upload the antibody sequences you need and let Twist do the rest.
In the antibody development pipeline, researchers often experience a bottleneck when transitioning from biopanning to antibody characterization. The high-throughput nature of technologies like phage-display and single B-cell sequencing make it possible to identify hundreds to thousands of potentially high-affinity antibodies for development. Further study of these hits requires expression as full-length antibodies—a process that is often low-throughput, resource-intensive, and a significant hurdle to progress.
Twist High-Throughput Antibody Production relieves this bottleneck by leveraging Twist’s expertise in automated DNA synthesis and antibody production to simultaneously produce thousands of distinct antibodies for screening and discovery purposes. With high-throughput production of antibodies in quantities ranging from 15 µg to 2000 µg—sufficient to identify candidates for further study—Twist provides a premium quality product without a premium price tag. Twist uses the industry workhorse HEK-293 transient expression system for robust, reproducible, and scalable yields. Because expression yields can vary depending on the antibody sequence, Twist uses and reports results from control sequences to provide confidence that transfection and protein production are functioning properly.
Shown below is a whisker plot demonstrating typical protein yields from Twist High-Throughput Antibody Production over a one-month time span. Briefly, a control antibody was recombinantly expressed in transient HEK-293 cells by transfecting two clonal genes encoding a matching heavy and light chain. After transfection, the cells were cultured for four days, briefly spun down, and supernatants were decanted into Protein A/G purification columns, followed by A280 quantitation. This data highlights the quality you can expect from the Twist High-Throughput Antibody Production workflow.
To ensure that antibodies are ready for experimentation “out of the box”, quality control (QC) of purified antibodies includes A280 quantitation, size (kDa) and percent purity analysis with a capillary electrophoresis sodium dodecyl sulfate (CE-SDS) assay. After passing QC, the antibody is prepared for shipping unless buffer exchange or volume normalization was requested.
Shown below are typical QC results generated using Twist’s High-Throughput Antibody Production workflow. The clean peaks in (A) and clean bands in (B) show that species within the antibody stock are all of similar size and charge. The peak at 67 kD represents the heavy-chain segment of the antibody, while the peak at 29 represents the light-chain segments.
The canonical protocol for Protein Express LabChip is followed to prepare denatured samples for both size and purity analysis. Capillary electrophoresis sodium dodecyl sulfate (CE-SDS) assay is run to collect sizing data benchmarked to a ladder, akin to an SDS-PAGE gel to provide approximate molecular weight (kDa), as well as a percent purity for both heavy and light chains.
In the antibody development pipeline, researchers often experience a bottleneck when transitioning from biopanning to antibody characterization. The high-throughput nature of technologies like phage-display and single B-cell sequencing make it possible to identify hundreds to thousands of potentially high-affinity antibodies for development. Further study of these hits requires expression as full-length antibodies—a process that is often low-throughput, resource-intensive, and a significant hurdle to progress.
Twist High-Throughput Antibody Production relieves this bottleneck by leveraging Twist’s expertise in automated DNA synthesis and antibody production to simultaneously produce thousands of distinct antibodies for screening and discovery purposes. With high-throughput production of antibodies in quantities ranging from 15 µg to 2000 µg—sufficient to identify candidates for further study—Twist provides a premium quality product without a premium price tag. Twist uses the industry workhorse HEK-293 transient expression system for robust, reproducible, and scalable yields. Because expression yields can vary depending on the antibody sequence, Twist uses and reports results from control sequences to provide confidence that transfection and protein production are functioning properly.
Shown below is a whisker plot demonstrating typical protein yields from Twist High-Throughput Antibody Production over a one-month time span. Briefly, a control antibody was recombinantly expressed in transient HEK-293 cells by transfecting two clonal genes encoding a matching heavy and light chain. After transfection, the cells were cultured for four days, briefly spun down, and supernatants were decanted into Protein A/G purification columns, followed by A280 quantitation. This data highlights the quality you can expect from the Twist High-Throughput Antibody Production workflow.
To ensure that antibodies are ready for experimentation “out of the box”, quality control (QC) of purified antibodies includes A280 quantitation, size (kDa) and percent purity analysis with a capillary electrophoresis sodium dodecyl sulfate (CE-SDS) assay. After passing QC, the antibody is prepared for shipping unless buffer exchange or volume normalization was requested.
Shown below are typical QC results generated using Twist’s High-Throughput Antibody Production workflow. The clean peaks in (A) and clean bands in (B) show that species within the antibody stock are all of similar size and charge. The peak at 67 kD represents the heavy-chain segment of the antibody, while the peak at 29 represents the light-chain segments.
The canonical protocol for Protein Express LabChip is followed to prepare denatured samples for both size and purity analysis. Capillary electrophoresis sodium dodecyl sulfate (CE-SDS) assay is run to collect sizing data benchmarked to a ladder, akin to an SDS-PAGE gel to provide approximate molecular weight (kDa), as well as a percent purity for both heavy and light chains.
